Education
About Us
Working with TipRanks
Follow Us
Sanofi (FR:SAN)
:SAN
SAN Stock Chart & Stats
Day’s Range― - ―
52-Week Range€85.07 - €110.88
Previous CloseN/A
Volume78.83K
Average Volume (3M)2.29M
Market Cap
$122.19B
Enterprise Value€128.59B
Total Cash (Recent Filing)€6.38B
Total Debt (Recent Filing)€14.53B
Price to Earnings (P/E)22.4
Beta0.54
Next Earnings
Apr 24, 2025EPS Estimate
1.7Next Dividend Ex-Date
May 12, 2025Dividend Yield3.7%
Share Statistics
EPS (TTM)4.44
Shares Outstanding1,233,566,000
10 Day Avg. Volume2,565,381
30 Day Avg. Volume2,294,470
Financial Highlights & Ratios
PEG Ratio7.79
Price to Book (P/B)N/A
Price to Sales (P/S)3.87
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€114.47Price Target Upside19.24% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Pipeline And Growth PotentialSanofi's strong pipeline includes multiple upcoming catalysts, supporting the stock's potential.
Valuation And Earnings GrowthSanofi shares are seen as compelling due to an attractive valuation and accelerating earnings growth.
Bears Say
Asthma Study Readout DelaysCaution is advised regarding the asthma study readout for amlitelimab, as results are expected later than initially anticipated.
Competitive LandscapeThere is crowding in the hidradenitis suppurativa competitive landscape by the end of the decade.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
13.12%
Mutual Funds
<0.01% Other Institutional Investors
72.02% Public Companies and
Individual Investors
SAN FAQ
What was Sanofi’s price range in the past 12 months?
Sanofi lowest stock price was €85.07 and its highest was €110.88 in the past 12 months.
What is Sanofi’s market cap?
Sanofi’s market cap is $122.19B.
When is Sanofi’s upcoming earnings report date?
Sanofi’s upcoming earnings report date is Apr 24, 2025 which is in 18 days.
How were Sanofi’s earnings last quarter?
Sanofi released its earnings results on Jan 30, 2025. The company reported €1.31 earnings per share for the quarter, missing the consensus estimate of €1.353 by -€0.043.
Is Sanofi overvalued?
According to Wall Street analysts Sanofi’s price is currently Undervalued.
Does Sanofi pay dividends?
Sanofi pays a Annually dividend of €3.92 which represents an annual dividend yield of 3.7%. See more information on Sanofi dividends here
What is Sanofi’s EPS estimate?
Sanofi’s EPS estimate is 1.7.
How many shares outstanding does Sanofi have?
Sanofi has 1,233,566,000 shares outstanding.
What happened to Sanofi’s price movement after its last earnings report?
Sanofi reported an EPS of €1.31 in its last earnings report, missing expectations of €1.353. Following the earnings report the stock price went up 1.728%.
Which hedge fund is a major shareholder of Sanofi?
Currently, no hedge funds are holding shares in FR:SAN
---
Company Description
Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through three segments: Pharmaceuticals, Vaccines, and Consumer Healthcare. The company provides specialty care products, including human monoclonal antibodies; products for multiple sclerosis, neurology, other inflammatory diseases, immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes; and cardiovascular and established prescription products. It also supplies poliomyelitis, pertussis, and hib pediatric vaccines; and influenza, adult booster, meningitis, and travel and endemic vaccines. In addition, the company offers allergy, cough and cold, pain, liver care, physical and mental wellness, probiotics, digestive, and nutritional products; and other products, such as daily body lotions, anti-itch products, moisturizing and soothing lotions, and body and foot creams, as well as powders for eczema. Further, it has various pharmaceutical products and vaccines in development stage. Sanofi has collaboration agreement with GlaxoSmithKline to develop a recombinant Covid-19 vaccine; and a research collaboration with Stanford University School of Medicine to advance the understanding of immunology and inflammation through open scientific exchange. It also has a collaboration and license option agreement with Prellis Biologics, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
---
SAN Company Deck
---
SAN Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment overall, driven by strong sales growth, successful product launches, and significant R&D advancements. Despite some challenges like gross margin pressure and increased expenses, the company's strategic focus on innovation and market expansion supports a strong outlook.Read More>---
SAN Stock 12 Month Forecast
Average Price Target
€114.47
▲(19.24% Upside)
Technical Analysis
Best Analysts Covering SAN
1 Year
1 Year Success Rate
16/22 ratings generated profit
1 Year Average Return
+3.66%
reiterated a buy rating 2 months ago
Copying Graham Parry's trades and holding each position for 1 Year would result in 72.73% of your transactions generating a profit, with an average return of +3.66% per trade.
---